Andreas Maddux, MD
Nephrology · Birmingham, ALNPI 1316985062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 384 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Bayer$1K
- Amarin Pharma, Inc.$469
- Lilly USA, LLC$436
- Otsuka America Pharmaceutical, Inc.$416
- plus $3K from 32 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$50
What the payments were for
- Food & beverage$7,48999%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 45 | $1,234 |
| Novo Nordisk | 58 | $1,091 |
| Bayer | 46 | $1,004 |
| Amarin Pharma, Inc. | 31 | $469 |
| Lilly USA, LLC | 26 | $436 |
| Otsuka America Pharmaceutical, Inc. | 22 | $416 |
| Amgen(2 entities) | 21 | $403 |
| Boehringer Ingelheim | 14 | $255 |
| Calliditas Therapeutics US Inc. | 10 | $200 |
| Corcept Therapeutics | 8 | $175 |
| Exact Sciences | 9 | $168 |
| Paratek Pharmaceuticals, Inc. | 8 | $153 |
| Vifor Pharma, Inc. | 10 | $148 |
| Dexcom, Inc. | 8 | $142 |
| Phathom Pharmaceuticals, Inc. | 6 | $123 |
| Fresenius USA Marketing, Inc. | 5 | $106 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Kowa Pharmaceuticals America, Inc. | 7 | $99 |
| Travere Therapeutics, Inc. | 3 | $79 |
| Arbor Pharmaceuticals, Inc. | 4 | $73 |
| Merck | 4 | $73 |
| GSK | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Akebia Therapeutics Inc | 3 | $61 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Novartis | 2 | $51 |
| Abbott | 3 | $48 |
| Pfizer | 2 | $46 |
| OPKO Pharmaceuticals, LLC | 2 | $34 |
| Eisai Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Intra-sana Laboratories | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,564 in reported general payments places this provider in the 80th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 99 | $111,159 |
| FarxigaDapagliflozin Propanediol | 125 | $99,650 |
| TrulicityDulaglutide | 73 | $97,721 |
| JanuviaSitagliptin Phosphate | 79 | $61,067 |
| OzempicSemaglutide | 36 | $48,041 |
| MounjaroTirzepatide | 34 | $44,719 |
| TradjentaLinagliptin | 20 | $22,984 |
| KerendiaFinerenone | 30 | $21,074 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $19,842 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $17,968 |
| Icosapent Ethyl | 49 | $16,285 |
| LinzessLinaclotide | 14 | $15,231 |
| EliquisApixaban | 17 | $15,219 |
| MyrbetriqMirabegron | 18 | $14,323 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $9,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30 | $436 | $145,657121 claims |
| Boehringer IngelheimJardiance, Tradjenta | $255 | $134,143119 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $1,234 | $116,190152 claims |
| MerckJanuvia | $73 | $61,06779 claims |
| Novo NordiskOzempic | $1,091 | $48,04136 claims |
| BayerKerendia | $1,004 | $21,07430 claims |
| PfizerEliquis | $46 | $15,21917 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $14,32318 claims |
| GSKBreo Ellipta | $71 | $8,52715 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $73 | $6,74818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 nephrology providers in Alabama.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
- Ashita TolwaniBirmingham$56K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.